A Road Less Followed

Our story is unique in the world of life sciences investing. We are located at the HudsonAlpha Institute of Biotechnology in Huntsville, Alabama. Not Boston or San Francisco. And unlike the majority of biotech companies, our founding and funding did not follow the traditional, institutional venture capital route.

From our founding in 2007 up until our going public merger transaction, we have been largely funded by our founders and investors in the Huntsville life sciences and technology community. These investors followed the team to Serina after the successful exit (via acquisition by Nektar Therapeutics) of the founding team’s prior company, Shearwater Polymers.

At Shearwater, Serina co-founders Dr. Milton Harris and Dr. Michael Bentley developed the first-generation of PEGylated drugs. The PEG platform has enabled 30 FDA approved PEGylated drugs that have since generated well over $100B in cumulative sales.

Serina was founded to create a next generation polymer therapeutic that addresses the limitations of PEG — enabling new treatment paradigms for patients suffering from some of the world’s most challenging diseases.